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Abstract
Background: The study was designed to test the hypothesis that granulosa cell (GC) gene expression response
differs between recombinant FSH and human menopausal gonadotropin (hMG) stimulation regimens.
Methods: Females < 35 years-old undergoing IVF for tubal or male factor infertility were prospectively randomized
to one of two stimulation protocols, GnRH agonist long protocol plus individualized dosages of (1) recombinant (r)
FSH (Gonal-F) or (2) purified human menopausal gonadotropin (hMG; Menopur). Oocytes were retrieved 35 h post-
hCG, and GC were collected. Total RNA was extracted from each GC sample, biotinylated cRNA was synthesized,
and each sample was run on Human Genome Bioarrays (Applied Microarrays). Unnamed genes and genes with
<2-fold difference in expression were excluded.
Results: After exclusions, 1736 genes exhibited differential expression between groups. Over 400 were categorized
as signal transduction genes, ~180 as transcriptional regulators, and ~175 as enzymes/metabolic genes. Expression
of selected genes was confirmed by RT-PCR. Differentially expressed genes included A kinase anchor protein 11
(AKAP11), bone morphogenetic protein receptor II (BMPR2), epidermal growth factor (EGF), insulin-like growth
factor binding protein (IGFBP)-4, IGFBP-5, and hypoxia-inducible factor (HIF)-1 alpha.
Conclusions: Results suggest that major differences exist in the mechanism by which pure FSH alone versus FSH/
LH regulate gene expression in preovulatory GC that could impact oocyte maturity and developmental
competence.
Background
Follicle development during the menstrual cycle is
directly controlled by gonadotropin (FSH and LH) sti-
mulation from the pituitary, as well as complex para-
crine and autocrine regulation within the ovary that is
modulated by the hormonal and metabolic environment.
FSH and LH elicit receptor-mediated actions directly on
granulosa and theca cells of the follicle, which in turn
regulate the maturation and development of the oocyte.
The oocyte reciprocally communicates with the follicu-
lar somatic cells to modulate their activity. In assisted
reproductive procedures such as in vitro fertilization
(IVF), follicle development is controlled by administra-
tion of pharmacologic preparations of human gonado-
tropins. Human menopausal gonadotropins (hMG)
containing both FSH and LH activities, purified from
the urine of post-menopausal women, have been used
successfully in the clinical setting for many years.
Advances in purification techniques have led to a new
generation of hMG preparations that are very consistent
in their FSH and LH bio-activities [1]. In recent years,
genetic engineering technology has allowed for the pro-
duction of recombinant (r)FSH. These preparations are
extremely pure and have no LH activity [2].
Both hMG and rFSH stimulation protocols are widely
used in clinical ART programs. Although neither of
these strategies perfectly mimics the natural ovarian
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Nevertheless physiologists and clinicians continue to
debate which stimulation type yields oocytes with opti-
mal developmental competence. Studies comparing the
efficacy of rFSH versus hMG stimulation have generally
focused on pregnancy and implantation rates [3-7].
Results of these studies, even those of prospective, ran-
domized design, are inconsistent and difficult to inter-
pret because of the many confounding variables that
affect outcomes. Very few studies have addressed the
impact of specific gonadotropin preparations on the cel-
lular physiology of follicular cells.
Even though FSH and LH both act primarily via
cAMP/PKA-mediated pathways, they are clearly not
identical in their signaling pathways and gene targets
[8]. Moreover, both FSH and LH interact with other
ligand-receptor pathways, e.g. IGF, that modulate their
actions, and are dependent upon the specific stage of
the cycle. For example, FSH activates protein kinase B/
Akt and glucocorticoid-induced kinase in growing folli-
cles, whereas LH induces progesterone receptor in preo-
vulatory granulosa cells [8].
DNA microarray technology can screen the relative
expression of the human genome from a single mRNA
extract of tissue or isolated cells. The purpose of this
study was to test the hypothesis that granulosa cell (GC)
gene expression response differs between pure recombi-
nant FSH and human menopausal gonadotropin (hMG)
stimulation regimens. If so, differences in gene expres-
sion may subsequently reveal altered signaling, tran-
scription/translation, or metabolic pathways that could
impact oocyte maturation and developmental
competence.
Methods
Patient selection & tissue acquisition
T h es t u d yw a sa p p r o v e db yt h eU n i v e r s i t yo fS o u t h
Dakota Institutional Review Board, and all participants
signed informed consent. Female patients (n = 8; 4 per
treatment) under 35 years-old undergoing IVF for tubal
or male factor infertility were prospectively randomized
to one of two stimulation protocols, GnRH agonist
(Lupron®, TAP Pharmaceutical) long protocol plus (1)
recombinant (r)FSH (Gonal-F®, Serono) or (2) purified
human menopausal gonadotropin (hMG; Menopur®;
Ferring, 75 IU FSH/75 IU LH activity per vial). Patients
received individualized dosages of only rFSH or only
hMG. Follicle development was monitored by ultrasono-
graphy and serum estradiol concentrations. When at
least two follicles were ≥ 17 mm, hCG (10,000 IU;
Novarel®, Ferring) was administered.
Oocytes were retrieved 35 hours post-hCG. All folli-
cles ≥15 mm in diameter were aspirated into HEPES-
buffered HTF (SAGE®). Immediately following oocyte
recovery from each aspirate, remaining fluid was col-
lected in 50-ml conical tubes containing RNALater®
(Applied Biosystems) and kept on ice until the end of
the retrieval. Pooled aspirates from all follicles were cen-
trifuged, washed once, and re-suspended in approxi-
mately 2 ml HEPES-buffered HTF, and then centrifuged
over 40% Percoll® (Sigma) gradients to remove the
majority of red blood cells (RBC). Each overlay was
washed in 4-5 volumes of HEPES-buffered HTF. The
final pellet was re-suspended in 1 ml RNALater®,a n d
snap-frozen in liquid nitrogen.
RNA extraction
Total RNA was extracted from each individual patient
sample. For extraction of RNA, GC were submerged in
TRI reagent (Molecular Research Center) and homoge-
nized. After homogenization, 105 μl 3 M sodium acet-
ate, and 350 μl bromochloropropane was added to the
supernate and mixed, and the sample was then incu-
bated on ice for 15 min. The sample was centrifuged
and the aqueous layer was removed and purified on an
RNeasy column (Qiagen). The sample was treated with
an on-column RNase-free DNase (Qiagen) to remove
any contaminating genomic DNA. The total RNA sam-
ple was then eluted from the column. The RNA quan-
tity and purity of the sample was analyzed using the
RNA 6000 Nano Lab chip on an Agilent Bioanalyzer
(Agilent Technologies). Total RNA obtained in indivi-
dual samples ranged from 0.3 μg to 47.6 μg. The RNA
extracts were stored at -70°C until all samples were
collected.
DNA microarrays
Total RNA extracts were labeled and run individually
on CodeLink Whole Human Genome Bioarrays (GE-
Amersham Biosciences). These microarrays contain
53,000 single-stranded 30-mer oligonucleotide probes
for human genes. For the labeling reaction, first-strand
cDNA was reverse transcribed from the total RNA
sample and second-strand cDNA was synthesized from
the first cDNA strand. Complementary RNA was
synthesized from the cDNA; this reaction incorporated
biotin-11-UTP into the cRNA. The synthesis of first
and second strand cDNA and synthesis of cRNA used
reagents from the CodeLink Expression Assay Reagent
Kit (GE-Amersham Biosciences) according to the man-
ufacturer’si n s t r u c t i o n s .O n es a m p l e( h M Gg r o u p )
yielded poor RNA recovery and was excluded from
microarray analysis.
The biotinylated cRNA was purified on Qiagen
RNeasy columns, fragmented, and hybridized with the
DNA microarrays for 18 hours at 37°C. The hybridized
slides were washed, incubated with streptavidin-Alexa
Fluor 647 (Molecular Probes/Invitrogen) to label the
Brannian et al. Reproductive Biology and Endocrinology 2010, 8:25
http://www.rbej.com/content/8/1/25
Page 2 of 6biotinylated cRNA hybridized to the slides, and washed
again. The slides were scanned with an Axon GenePix
Scanner and analyzed with GenePix Pro (MDS Analyti-
cal Technologies), CodeLink (GE-Amersham), Acuity
(MDS Technologies) and GeneSpring (Agilent Technol-
ogies) software. The GenePix Pro software was used to
obtain the microarray image. CodeLink software applied
the background correction. GeneSpring software was
used to normalize the expression of each gene to the
median gene expression and each slide to the 50
th per-
centile of gene expression and to perform statistical ana-
lysis. The data set for these DNA microarrays has been
deposited at the National Center for Biotechnology
Information Gene Expression Omnibus [GEO; [9]] as
recommended by Minimum Information about a Micro-
array Experiment [MIAME] standards (accession num-
ber GSE16523).
Real time RT-PCR
Pre-designed primers and fluorescent (FAM) labeled
minor groove binding probes were obtained from
Applied Biosystems. Real time RT-PCR was carried out
with TaqMan Gold RT-PCR reagents (Applied Biosys-
tems) as described [10]. Changes in relative expression
of genes of interest were calculated; data were normal-
ized to an endogenous control (GAPDH). An RNA con-
centration-response validation curve was carried out to
determine the concentration of RNA to add to the RT-
PCR reaction. All samples were run in duplicate. The
Relative Expression Software Tool (REST
©) [11] was
used for statistical analysis of the data from the real
time RT-PCR reaction. This analytical tool incorporates
the variability of data from both the housekeeping gene,
GAPDH, as well as that of the genes of interest when
calculating statistical significance.
Statistical analysis
GeneSpring software (Agilent Technologies) was used to
compare relative gene expression. This program per-
formed a t-test on the data for statistical analysis of the
DNA microarrays; p value was set at 0.05. Those genes
shown to be differentially expressed were sorted by
function; each gene was placed into only one gene
ontology. Unnamed genes were not further analyzed.
Genes for which the average expression values for both
rFSH and hMG were both less than 0.2 were also
excluded from further analysis, as were genes with < 2-
fold difference in expression between groups.
Results and Discussion
There were no differences in patient age, BMI, basal
FSH level, days of stimulation, number of mature folli-
cles, number of oocytes retrieved, or clinical pregnancy
rate between treatment groups (Table 1).
After the exclusions noted above, 1736 genes exhibited
≥ 2-fold differential expression between groups. Over
400 of these were categorized as signal transduction
genes, ~180 as transcriptional regulators, and ~175 as
enzymes/metabolic genes (Figure 1). A condensed list of
differentially expressed genes by functional category is
shown in Additional File 1, Table S1. The complete list
of differentially expressed genes is shown in Additional
F i l e2 ,T a b l eS 2 .T h ee n t i r ed a t as e tc a nb ea c c e s s e da t
GEO [9] using accession number GSE16523. Expression
of selected genes was confirmed by RT-PCR. Relative
expression by microarray and PCR were generally simi-
lar (Figure 2).
The results demonstrate thatg e n ee x p r e s s i o ni nG Co f
periovulatory follicles is highly dependent upon specific
gonadotropin regimens used for controlled ovarian sti-
mulation, and confirm a recent report by Grǿndahl, et
al. [12]. The present data are surprising in the large
number and functional diversity of genes that differ in
expression between recombinant FSH and hMG proto-
cols. The major difference between rFSH and hMG pre-
parations is the absence or presence of LH activity.
However, there are also differences in the FSH isoform
profiles and potentially in specific FSH activity that may
contribute to the differences in gene expression
observed. Discerning Differences in GC gene expression
have broad implications for oocyte maturation, early
embryo development, and clinical outcomes in ART
patients. The present results open the door for a new
line of investigation into the impact of GC gene regula-
tion on oocyte function.
GC were collected for analysis 35 h after administra-
tion of a standard dose of hCG, and were therefore
undergoing luteinization. The profound differences in
gene expression are all the more striking considering
that hCG was the dominant hormonal influence during
the preceding 35 hours in both groups. It is possible
that the hMG group had accelerated luteinization rela-
tive to the rFSH group due to prior LH exposure. For
example, 3-beta-hydroxysteroid dehydrogenase, IGFBP-
4, IGFBP-5, basigin, HIF-1alpha, vascular endothelial
Table 1 Patient demographics (n = 4 rFSH; n = 3 hMG;
mean ± SEM). (NS = not statistically significant.)
rFSH hMG significance
Age 29.8 ± 2.1 28.7 ± 4.1 NS
BMI 22.2 ± 0.9 22.3 ± 0.3 NS
Basal FSH 6.3 ± 0.4 6.7 ± 0.8 NS
Days of stimulation 9.3 ± 0.5 9.5 ± 1.1 NS
No. follicles ≥15 mm 12.3 ± 3.1 11.0 ± 4.0 NS
No. oocytes retrieved 13.5 ± 3.2 10.3 ± 3.3 NS
Total IU FSH 3337 ± 164 2900 ± 704 NS
Clinical Pregnancy Rate 2/4 2/3 NS
Brannian et al. Reproductive Biology and Endocrinology 2010, 8:25
http://www.rbej.com/content/8/1/25
Page 3 of 6growth factor (VEGF), and related genes were expressed
at greater levels in the hMG group, changes expected
during luteinization [13-18]. This suggests that many, if
not all, of the observed differences in gene expression in
GC were a manifestation of a distinct response to the
ovulatory/luteinizing stimulus that was determined by
the type of follicular stimulation the cells were exposed
to. It would be very interesting to repeat this experiment
in a non-human primate model where GC could be col-
lected without hCG administration [19,20].
The largest groups of differentially expressed genes
were those related to signal transduction and transcrip-
tional regulation. AKAP11, for example, was much more
highly expressed in rFSH-stimulated cells than in hMG-
stimulated cells. AKAP11 is a protein kinase A (PKA)
anchor protein, which binds both RI and RII PKA regu-
latory subunits, targeting PKA to specific intracellular
sites [21]. Although not studied in the ovary, AKAP11 is
highly expressed in the human testis where it is thought
to play an important role in spermatogenesis [22].
In addition to numerous signaling proteins involved in
cAMP signaling pathways, genes involved in other sig-
naling pathways were differentially expressed. For exam-
ple, signal transducer and activator of transcription
(STAT) 5B and STAT 6, suppressor of cytokine signaling
(SOCS) 1 and SOCS 5, and several members of mitogen-
activated protein (MAP) kinase cascades. Numerous
receptor genes were differentially expressed, e.g. bone
morphogenetic protein (BMP) receptors type 1A, 1B,
and 2, adiponectin receptor, and histamine (H1) recep-
tor. There were also genes encoding signaling ligands
that differed between groups, such as growth
Figure 2 Comparison of mean relative (hMG:rFSH) gene
expression of selected genes by DNA microarray (gray bars)
and RT-PCR (black bars). The expression of each gene of interest
was calculated relative to that of GAPHD, then the expression in
hMG-treated samples was divided by that of the rFSH-treated
samples. For both sets of data, the values represent the ratios of the
group means.
Figure 1 Differentially expressed genes by functional category. Black bars represent genes with greater expression in rFSH-stimulated GC (n
= 4); gray bars represent genes with greater expression in hMG-stimulated GC (n = 3).
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Page 4 of 6differentiation factor (GDF) 15, GDF 11,t r a n s f o r m i n g
growth factor B1 (TGFB1), and epidermal growth factor
(EGF). The results demonstrate that differences in gona-
dotropin stimulation can significantly impact multiple
aspects of regulatory granulosa cell signaling pathways.
It remains to be elucidated how these differences may
affect oocyte and luteal function.
Among the differentially expressed genes were several
with known importance to oocyte maturation. Notably,
the BMP family receptors (BMPR1A, BMPR1B, BMPR2),
are the receptors for GDF-9 and BMP-15 [23,24]. GDF-
9 and BMP-15 are oocyte-derived factors that are major
mediators of oocyte-granulosa cell communication dur-
ing folliculogenesis and the periovulatory period [25,26].
The five-fold reduction in BMPR2 expression in hMG-
stimulated GC relative to rFSH-stimulated GC suggests
that they may be less responsive to GDF-9, at least at
the time point sampled. Consistent with lesser BMPR2
expression, the gene encoding the downstream signaling
protein SMAD5 was 3-fold less in hMG-stimulated GC.
Whether these differences indicate a fundamental differ-
ence in function, or represent only a temporal difference
i nt h en o r m a ls e q u e n c eo fp e r i o v u l a t o r ye v e n t si sn o t
known. Nevertheless, even a temporal difference in
GDF-9/BMP-15 signaling could have significant effects
on oocyte quality and developmental potential.
Moreover, the differential expression of certain key
metabolic enzyme genes implies a major shift in meta-
bolic pathways. For example, hMG-stimulated GC had a
more than a 5-fold greater expression of pyruvate
kinase, whereas rFSH-stimulated GC had greater expres-
sion of malate dehydrogenase and lactate dehydrogen-
ase. The oocyte derives most of its cellular energy from
pyruvate synthesized via glycolysis in cumulus GC,
which is regulated by oocyte-derived factors such as
BMP-15, GDF-9, and fibroblast growth factor (FGF)
[27]. Differences in BMP-15/GDF-9 signaling may be
directly related to differential metabolic gene expression
in hMG- versus rFSH-stimulated GC. Although the
majority of GC collected in the present study were
mural GC, the results suggest possible differences in
oocyte energy substrate availability, which could impact
oocyte developmental competence.
In a recent similar study [12], only 85 genes were
found to be differentially expressed in GC from women
stimulated with rFSH or hMG. Pooling of patient sam-
ples, use of a different microarray system, and use of
different statistical software [12] may account for differ-
ences in results. However, among the genes identified in
that study were several associated with lipid metabolism
and protein signaling/phosphorylation, as in the present
study. Differentially expressed genes that were com-
monly identified in both studies include 3-hydroxy-3-
methyl-Coenzyme A synthase 1, fibrinogen gamma
polypeptide, phosphoinositide-3-kinase alpha polypep-
tide, SOCS 1, transferrin receptor (CD71), and multiple
protein tyrosine phosphatases (non-receptor type).
Future studies will be directed towards more in depth
investigation of the regulation and function of some of
the genes and gene pathways revealed in this study. For
example, cell culture studies performed under more
controlled in vitro conditions may distinguish between
temporal differences in gene expression related to GC
maturation in response to FSH and LH versus more
fundamental differences in FSH and LH signaling.
Moreover, genes not previously studied in the ovary
may reveal important new regulatory mechanisms.
Conclusions
GC recovered from IVF patients at oocyte retrieval who
were stimulated with either rFSH or hMG displayed
strikingly different profileso fg e n ee x p r e s s i o n .S o m eo r
all of these differences may reflect divergent timing of
periovulatory events. Nevertheless, considering our cur-
rent understanding of the intimate relationship between
GC and oocyte function, differential gene expression in
GC strongly implies that gonadotropin stimulation pro-
tocols for IVF could have a major impact on oocyte
functional status. The present results should open up
new lines of discussion and research regarding optimal
gonadotropin stimulation for ART, as well as for better
understanding fundamental aspects of folliculogenesis,
ovulation, oocyte maturation, and luteinization.
Additional file 1: Condensed list of differentially expressed genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-7827-8-25-
S1.PDF]
Additional file 2: Complete list of differentially expressed genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-7827-8-25-
S2.XLS]
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